Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.

被引：0

作者：

Rea, Delphine

Mauro, Michael J.

Hochhaus, Andreas

Boquimpani, Carla

Lomaia, Elza

Voloshin, Sergey

Turkina, Anna G.

Kim, Dong-Wook

Apperley, Jane

Cortes, Jorge E.

Sasaki, Koji

Kapoor, Shruti

Allepuz, Alex

Quenet, Sara

Bedoucha, Veronique

Minami, Yosuke

机构：

[1] Hop St Louis, Paris, France

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[4] HEMORIO, State Inst Hematol Arthur Siquiera Cavalcanti, Rio De Janeiro, Brazil

[5] Almazov Natl Med Res Ctr, Minist Hlth, St Petersburg, Russia

[6] Russian Res Inst Hematol & Transfusiol, St Petersburg, Russia

[7] Natl Res Ctr Hematol, Moscow, Russia

[8] Uijeongbu Eulji Med Ctr, Uijeongbu Si, South Korea

[9] Imperial Coll London, Ctr Haematol, London, England

[10] Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA USA

[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[12] Novartis Pharmaceut, E Hanover, NJ USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Kobe Univ Hosp, Dept Transfus Med & Cell Therapy, Kobe, Hyogo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7004

引用

页数：1

共 50 条

[21] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
Abdelall, Waleed
Kantarjian, Hagop M.
Devendra, K. C.
Akosile, Mary
Borthakur, Gautam
Verstovsek, Srdan
Daver, Naval
Pemmaraju, Naveen
Naqvi, Kiran
Garcia-Manero, Guillermo
Thompson, Philip A.
Ferrajoli, Alessandra
Ravandi, Farhad
Konopleva, Marina
DiNardo, Courtney D.
Jabbour, Elias J.
Cortes, Jorge E.
BLOOD, 2017, 130
[22] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
Jabbour, Elias
Kantarjian, Hagop
Shan, Jenny
O'Brien, Susan
Wierda, William
Ravandi, Farhad
Borthakur, Gautant
Komblau, Steven
Walker, Brenda K.
Rios, Mary Beth
Cortes, Jorge
BLOOD, 2007, 110 (11) : 577A - 577A
[23] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
Sasaki, Koji
Kantarjian, Hagop M.
O'Brien, Susan M.
Ravandi, Farhad
Konopleva, Marina
Borthakur, Gautam
Garcia-Manero, Guillermo
Wierda, William G.
Daver, Naval
Ferrajoli, Alessandra
Takahashi, Koichi
Jain, Preetesh
Rios, Mary B.
Pierce, Sherry
Jabbour, Elias J.
Cortes, Jorge E.
BLOOD, 2017, 130
[24] Trial in Progress: a phase III Study of Asciminib versus an investigator-selected Tyrosine Kinase Inhibitor (TKI) in Patients with newly diagnosed chronic myeloid Leukemia in chronic Phase (CML-CP)
Hochhaus, A.
Le Coutre, P.
Brummendorf, T. Henrik
Saussele, S.
Lang, F.
Von Bubnoff, N.
Petzer, A.
Gleixner, K.
Balabanov, S.
Stussi, G.
Cortes, J.
Takahashi, N.
Larson, R.
Issa, G.
Bombaci, F.
Ramscar, N.
Kapoor, S.
Ifra, S.
Hughes, T.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 121 - 122
[25] Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
Bruemmendorf, T. H.
Gambacorti-Passerini, C.
Kindler, T.
Saussele, S.
Kim, D. W.
Goh, Y. T.
Dyagil, I
Pagnano, K.
Batai, A.
Turkina, A. G.
Leip, E.
Purcell, S.
Leone, J.
Viqueira, A.
Cortes, J. E.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 70 - 71
[26] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
Atallah, Ehab L.
Sadek, Islam
Wei, David
Latremouille-Viau, Dominick
Rossi, Carmine
Damon, Andrea
Yang, Daisy
Bellefleur, Remi
Guerin, Annie
Jadhav, Kejal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
[27] Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience
Moeen, Sawsan M.
Afifi, Ola A.
Thabet, Ahmad F.
Saleh, Medhat A.
Morad, Mohamed A.
EGYPTIAN JOURNAL OF HAEMATOLOGY, 2023, 48 (02): : 185 - 190
[28] Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
Gambacorti-Passerini, Carlo
Brummendorf, Tim H.
Kim, Dong-Wook
Goh, Yeow Tee
Dyagil, Irina S.
Pagnano, Katia
Batai, Arpad
Turkina, Anna G.
Leip, Eric
Purcell, Simon
Leone, Jocelyn M.
Viqueira, Andrea
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study
Gjertsen, Bjorn T.
Hochhaus, Andreas
Rosti, Gianantonio
Watts, Justin M.
Orti, Guillermo
le Coutre, Philipp
Leip, Eric
Viqueira, Andrea
Cortes, Jorge E.
Giles, Frank
Gambacorti-Passerini, Carlo
BLOOD, 2019, 134
[30] Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study.
Saussele, Susanne
Gambacorti-Passerini, Carlo
Gutierrez, Valentin Garcia
Abboud, Camille N.
Purcell, Simon
Viqueira, Andrea
Leip, Eric
Ernst, Thomas
Giles, Frank
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →